)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
OmniAb
OmniAb (OABI) investor relations material
OmniAb Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary9 Mar, 2026
Mission and business overview
Aims to accelerate innovative therapeutic development by advancing drug discovery technologies.
Licenses proprietary discovery technology globally, supporting antibodies, multispecifics, CAR-T, radiopharmaceuticals, and peptides.
Ecosystem includes over 100 partners, with technologies addressing large and growing pharma markets.
Business model aligns economic and scientific interests through upfront fees, milestones, service revenue, and royalties.
Technology and innovation
Platforms generate diverse, high-quality antibodies using engineered animals and proprietary reagents.
Recent launches include OmniUltra (transgenic chicken with ultralong CDRH3 domains) and xPloration (partner access program).
Suite of in silico tools, bioinformatics, and AI enhance discovery and optimization.
Biological Intelligence leverages in vivo antibody generation for improved specificity and developability.
Market trends and demand drivers
Antibody therapeutics have higher regulatory approval rates than small molecules (12.1% vs. 7.5%).
Industry shifting R&D investment toward antibody-based drugs, partly due to regulatory changes like the Inflation Reduction Act.
Antibody drug market projected to exceed $330 billion by 2029; peptide TAM estimated over $1 trillion by 2034.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OmniAb
- 107 partners, 407 programs, new platforms, and 2026 revenue growth expected.OABI
Q4 20254 Mar 2026 - Q2 revenue up 10% to $7.6M, net loss narrowed, and partnerships and cash remain strong.OABIQ2 20242 Feb 2026
- Expanding partnerships and innovative antibody platforms drive growth and long-term royalties.OABIJefferies Global Healthcare Conference31 Jan 2026
- Q3 revenue fell to $4.2M, but partner and program growth and $59.4M cash support future progress.OABIQ3 202414 Jan 2026
- Double-digit partner and program growth, Q4 revenue up, 2025 revenue seen at $20–$25M.OABIQ4 202424 Dec 2025
- Resale registration covers 21.25M shares from a $30M private placement; no proceeds to company.OABIRegistration Filing16 Dec 2025
- OmniUltra enables novel antibody and peptide discovery, targeting a trillion-dollar market.OABIInvestor Update16 Dec 2025
- Annual meeting to elect directors and ratify auditor, with focus on governance and ESG.OABIProxy Filing2 Dec 2025
- Votes will be held on two director nominees and auditor ratification at the June 2025 meeting.OABIProxy Filing2 Dec 2025
Next OmniAb earnings date
Q1 20267 May, 2026
OmniAb
Next OmniAb earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage